In the past 12 months, COVID-19 has irrevocably upended the state of patient care in the United States, with many of these changes likely to persist indefinitely. Already a growing sector of the healthcare industry, digital therapeutics (DTx) and remote-care technology quickly became buzzwords within the industry as millions of practices, physicians, and patients engaged with the technology. Broader familiarity with and support for telehealth and digital healthcare tools among physicians and patients has been a boon for digital therapeutics manufacturers eager to extol the virtues and value of these technologies.
In addition to providing opportunities for innovation, the pandemic has exposed vulnerabilities and gaps within our healthcare system:
- Mental health professionals, while already understaffed to treat the current patient population, are expected to see a massive rise in the number of patients and services requested in the wake of COVID-19.
- Digital therapeutics show promise in addressing these demands, but the extent of their effectiveness will depend entirely on their adoption and level of access provided by insurers.
- Payers are adamant about their internal evaluation frameworks for digital therapeutics, and it is essential that all manufacturers be mindful of these throughout the commercial process in order to ensure the successful launch of their digital solutions.
Download our latest paper for detailed insights to help you design more innovative DTx solutions and meet the surging demand for mental health services expected over the next decade.
For more on this topic, please revisit our recorded webinar.
[WEBINAR] Why digital analysis is critical for pharma marketers
Join us for a complimentary webinar as Ipsos VP of Healthcare Digital Strategy Steve Reeves will take you through a pragmatic, detailed process for understanding how to think about digital readiness and the utilization of social and other digital data sources for insights gathering in healthcare.